A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers

UCB

Status and phase

Completed

Phase 1

Conditions

Human Volunteers

Treatments

Drug: Levetiracetam

Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01618877

N01362B

Details and patient eligibility

About

The part B of N01362 is to assess the pharmacokinetic profile of Levetiracetam 1500 mg intravenous (iv) infusion during repeated dosing in Chinese healthy volunteers.

Full description

The study includes 2 parts, part A is to evaluate the bioequivalence of Levetiracetam (LEV) 1500 mg intravenous (iv) infusion when compared to oral tablet, part B is to assess the pharmacokinetic profile of LEV infusion during repeated dosing in Chinese healthy volunteers.

Enrollment

24 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Chinese, age 18-40, weight ≥ 50 kg
Healthy volunteers with normal vital signs, good physical and mental health status and normal electrocardiogram and laboratory test

Exclusion criteria

History or presence of each systems disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication
History or presence of drug addiction or excessive use of alcohol
Symptomatic or asymptomatic Orthostatic Hypotension at screening
Current smokers and former smokers
Heavy caffeine drinker
History of frequent and severe headache
Any drug treatment
Subjects who are known to have Serum Hepatitis or who are carriers of the Hepatitis B surface antigen, or Hepatitis C antibody or who are HIV positive
Subjects on a controlled sodium diet
Subject has made a blood donation or had a comparable blood loss